Nicky Forster

Sep 23, 2024 | bismarcktribune.com | Matthew Perrone |Nicky Forster

FDA | OVERSIGHTAs COVID-19 swept across the globe in early 2020, the Food and Drug Administration pulled most of its safety inspectors from the field, creating a massive backlog of uninspected pharmaceutical plants in the U.S. and overseas. Nearly five years later, The Associated Press wanted to assess the FDA's performance in catching up on inspections of factories that produce drugs used by millions of Americans.

Sep 16, 2024 | enidnews.com | Matthew Perrone |Nicky Forster

WASHINGTON (AP) — Federal regulators responsible for the safety of the U.S. drug supply are still struggling to get back to where they were in 2019, before the COVID-19 pandemic upended factory inspections in the U.S. and across the world, The Associated Press has found.

Sep 7, 2024 | carolinacoastonline.com | Matthew Perrone |Nicky Forster

WASHINGTON (AP) — Federal regulators responsible for the safety of the U.S. drug supply are still struggling to get back to where they were in 2019, before the COVID-19 pandemic upended factory inspections in the U.S. and across the world, The Associated Press has found.

Sep 6, 2024 | manufacturing.net | Nicky Forster |Matthew Perrone

WASHINGTON (AP) — As COVID-19 swept across the globe in early 2020, the Food and Drug Administration pulled most of its safety inspectors from the field, creating a massive backlog of uninspected pharmaceutical plants in the U.S. and overseas. Nearly five years later, The Associated Press wanted to assess the FDA's performance in catching up on inspections of factories that produce drugs used by millions of Americans.

Sep 6, 2024 | mbtmag.com | Nicky Forster |Matthew Perrone

WASHINGTON (AP) — As COVID-19 swept across the globe in early 2020, the Food and Drug Administration pulled most of its safety inspectors from the field, creating a massive backlog of uninspected pharmaceutical plants in the U.S. and overseas. Nearly five years later, The Associated Press wanted to assess the FDA's performance in catching up on inspections of factories that produce drugs used by millions of Americans.